Moderna stock has delivered a strong 84.8% return year to date, yet its low valuation score and expensive market multiples raise questions about how much of the story is already in the price.

• The 84.8% gain year to date signals that investors have sharply repriced Moderna as expectations around its pipeline and future revenue have shifted.
• Progress in areas such as the mRNA-4200 cancer program and the pending FDA decision on the mRNA-1010 flu vaccine can support growth hopes. At the same time, ongoing patent lawsuits and revenue uncertainty from respiratory vaccines may weigh on how much investors are willing to pay for that potential.
• With a value score of 1 out of 6, Moderna currently screens as leaning expensive rather than a clear bargain on the broader valuation checks.

The issue now is whether Moderna's recent rally leaves enough valuation cushion to justify the risks tied to its pipeline, legal disputes and revenue outlook.

Has Moderna Run Too Far on Sales?

P/S is often a better fit than P/E for Moderna because earnings are currently loss making and investors are anchoring more on revenue potential than near term profits.

Moderna trades on a P/S of 10.2x, compared with an industry average of 11.0x and a peer group average of 5.4x for biotechs. On Simply Wall St’s fair multiple framework, which adjusts for factors such as growth profile, margins, size and risk, Moderna’s tailored P/S is 2.6x. The current market price therefore implies a very large premium to that reference point.

Because the gap to this fair ratio is wide, the model is effectively flagging that Moderna screens as very expensive on a sales basis given its loss making status and risk profile, rather than pointing to a precise P/S level to target. Despite the recent sell off on respiratory vaccine revenue concerns, the stock still has a valuation that reflects investors’ willingness to pay for the pipeline and potential future sales.

On the P/S multiple, Moderna stock currently screens as overvalued compared with both tailored and broad biotech benchmarks.

The Moderna Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Moderna pick up where this valuation puzzle leaves off by spelling out which combinations of future revenue growth, margins and earnings would need to play out for Moderna's stock to be worth materially more or less than it is today on the market. Rather than relying on a single multiple or model output, each narrative lays out its own fair value assumptions so you can compare them with Moderna's actual results over time.

Community views on Moderna are sharply split, with one camp focused on the upside from the mRNA platform and another worried that expectations already look stretched.

Bull case: 14% undervalued

"Moderna's validated mRNA platform, intellectual property victories against competitors, and broadening pipeline in both infectious and rare diseases make it an attractive target for major strategic collaborations or acquisition, which could unlock further distribution scale and significant uplift to both topline and earnings..."

Bear case: 29% overvalued

"Slowing vaccine sales, higher competition, cost cuts, regulatory pressures, and limited capital flexibility threaten Moderna's revenue stability, pipeline breadth, and long-term earnings growth..."

Do you think there's more to the story for Moderna? Head over to our Community to see what others are saying!

The Bottom Line

For Moderna, the valuation picture skews toward overvalued on the market-multiple checks, with an extreme gap between current pricing and the tailored sales ratio. That reflects investors putting a high price on the pipeline despite loss making financials and the risk profile highlighted earlier. From here, the key question is whether Moderna can translate its mRNA programs into durable, sizable revenue streams that make this rich multiple feel justified rather than stretched.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.